Michelle Dawson, MD, AstraZeneca, talks about 75% Overall Response from Moxetumomab 41% of patients had complete response at Annual Meeting 2018.
75% Overall Response from Moxetumomab 41% of patients had complete response
Michelle Dawson, MD, AstraZeneca, talks about 75% Overall Response from Moxetumomab 41% of patients had complete response at Annual Meeting 2018.